Skip to Main Content
Professional Photo
Professionals

Lisa Gora

Shareholder

Lisa Gora, a shareholder in Baker Donelson's Metropark (Iselin), New Jersey office, provides comprehensive legal guidance to clients on regulatory compliance, corporate transactions, and emerging industries. With extensive experience in health care, cannabis, and psychedelic law, she is a trusted advisor to health care providers and businesses navigating complex regulatory frameworks.

Professional Biography


Health care providers and businesses turn to Ms. Gora for advice on regulatory compliance and representation in corporate transactions. She regularly advises health care professionals, group practices, hospitals, academic medical centers, ambulatory surgery centers, management service organizations, ambulatory care facilities, substance use treatment facilities, mental health facilities, and nursing homes.

Ms. Gora analyzes federal and state statutes and regulations, including the federal Anti-Kickback Statute and Stark Law, New Jersey's Codey Law, the federal and New Jersey False Claims Acts, licensing and reimbursement issues, Board of Medical Examiners regulations, and other fraud and abuse laws. She provides clients with guidance on mergers, acquisitions, entity formation, joint ventures, affiliation agreements, and management services arrangements. Ms. Gora also helps clients understand the complexities of ownership of health care practices and cannabis entities, particularly regarding buying into and separating from these practices.

With years of experience in the cannabis industry, Ms. Gora helps clients navigate the complex and evolving regulatory landscape. She represents alternative treatment centers in the medicinal cannabis space and advises startups and multi-state operators in the adult-use cannabis industry, including cultivators, manufacturers, retailers, distributors, delivery services, and testing laboratories. Ms. Gora assists with licensing, ownership, and regulatory compliance under state laws, as well as issues related to mergers and acquisitions. Additionally, she advises physicians, hospitals, and others on matters related to medicinal cannabis in New Jersey.

Ms. Gora's experience extends to the psychedelic sector as well. She guides researchers, academic medical centers, pharmaceutical manufacturers, and other stakeholders through the legal and regulatory challenges in this emerging field. She serves as co-chair of the psychedelic subcommittee of the New Jersey State Bar Association and is a former chair of the Health Law Section and past co-chair of the Cannabis Law Committee.

Ms. Gora was editor-in-chief of Health Care and the Business of Cannabis: Legal Questions and Answers, a pioneering publication by the American Health Law Association. She also co-authored "Medical Marijuana: State and Federal Law Thickets and Practical Implications" in the Health Law Handbook, published by Thomson Reuters in 2020.

Results may vary depending on your particular facts and legal circumstances.

  • Testified before the New Jersey Assembly Health, Human Services and Senior Citizens Committee in support of A 3852, the Psilocybin Behavioral Health Access and Services Act. The bill, which was approved by the majority of Assembly members, authorizes the production and use of psilocybin for patients assessed by licensed health care practitioners as benefiting from its therapeutic use. It tasks the New Jersey Department of Health with regulating psilocybin-related activities and establishing psilocybin service centers. The bill mandates the creation of a Psilocybin Advisory Board to develop guidelines, safety practices, and a strategic plan for psilocybin access.

No aspect of this advertisement has been approved by the Supreme Court of New Jersey.

  • Listed in Chambers USA as a leading Healthcare lawyer in New Jersey (2019 – 2024). This award is conferred by Chambers and Partners. A description of the selection methodology is available here.
  • Listed in The Best Lawyers in America® for Health Care Law (2024 – 2025). This award is conferred by Best Lawyers. A description of the selection methodology is available here.
  • Listed in Best Lawyers: Ones to Watch® in America for Corporate Law and Health Care Law (2022 – 2023) and Corporate Law (2021). This award is conferred by Best Lawyers. A description of the selection methodology is available here.
  • Listed in The Legal 500 United States for M&A Middle Market (Sub $500 Million) (2024). This award is conferred by The Legal 500. A description of the selection methodology is available here.
  • Named in New Jersey Law Journal: New Leader of the Bar (2020). This award is conferred by the New Jersey Law Journal. A description of the selection methodology is available here.
  • Selected for New Jersey Rising Stars for Health Care, Business/Corporate, Cannabis Law (2018 – 2024). This award is conferred by Thomson Reuters. A description of the selection methodology is available here.
  • Selected by NJBiz in its "Forty Under 40" (2024). This award is conferred by NJBIZ. A description of the selection methodology is available here.
  • Member – American Health Law Association (AHLA), Medical Staff, Credentialing, and Peer Review Practice Group Chair (2019 – present), Vice Chair (2016 – 2019)
  • Member – New Jersey State Bar Association, Psychedelic Subcommittee Co-chair (2024 – present); Cannabis Law Committee, Co-chair (2021 – 2023); Health Law Section Chair (2021 – 2022), Vice Chair (2019 – 2020), Secretary (2018 – 2019)
  • Member – Law360 Cannabis Editorial Board (2022 – 2023)
  • "Careers in Health Law," American Bar Association Health Law Section (March 2025)
  • "How to Engage Your Cannabis Audience About Psychedelics," reMind Psychedelics Business Forum (December 2024)
  • "The Legal and Regulatory Landscape of Psychedelics: Essential Information for Investors," The REAL Summit Fall 2024 (October 2024)
  • "The Law and Business of Cannabis and Psychedelics," 2024 American Academy of Legal Medicine (AALM) & Medical Association of Georgia (MAG) Education Conference (October 2024)
  • "The Status and Future of the Psychedelics Industry in New Jersey and Beyond," NECANN 2024 New Jersey Cannabis Convention (September 2024)
  • "Psilocybin Legalization: New York, New Jersey, Colorado," SoundMind Institute (July 2024)
  • "The Law of Psychedelics," Ms. Medicine (July 2024)
  • "The World of Alternative Substances in Health Care: The Rise in Interest for Use of Cannabis, Ketamine, and Psychedelics (Psilocybin/MDMA) as Emerging Therapies by Practitioners," American Health Law Association (AHLA) Annual Meeting (June 2024)
  • "Legal and Regulatory Challenges in Psychedelic Research and Commercialization," Blue Cross Blue Shield Association (June 2024)
  • "Business & Culture at a Crossroads: Cannabis & Psychedelics," 10th Annual Cannabis World Congress & Business Exposition (CWCBExpo) (June 2024)
  • "The World of Emerging Therapies and Alternative Substances in Healthcare," Blue Cross Blue Shield Association (May 2024)
  • "New Jersey Cannabis Regulations Two (and a Half) Years In: The Sticky and the Icky," NJSBA 6th Annual Cannabis and Psychedelics Law Symposium (April 2024)
  • "The World of Emerging Therapies and Alternative Substances in Healthcare," ABA Health Law Section 25th Annual Emerging Issues in Healthcare Law Conference (April 2024)
  • "New Jersey Cannabis Regulations Two (and a Half) Years In: The Sticky and the Icky," New Jersey Institute for Continuing Legal Education (NJICLE) Latest Developments in Cannabis and Psychedelics Law (March 2024)
  • "Noncompete and No-Poach Agreements in Healthcare: Navigating the FTC's Proposed Noncompete Rule, the DOJ's Criminal No-Poach Prosecutions, and Private Litigation," NJSBA Health Law Section (March 2024)
  • "The Corporate Transparency Act," NJSBA Health Law Section (February 2024)
  • "What a Difference Crossing the Hudson Makes: A Discussion of the New York and New Jersey Cannabis Regulatory Schemes," Cannabis Law Section of the New York State Bar Association (NYSBA) (January 2024)
  • "Before You Can Follow the Money, You Have to Determine the Best Strategy to Get the Money," International Cannabis Bar Association (INCBA) Cannabis Law Session (June 2023)
  • "Psychedelics: Law, Legislation, and Litigation in 2023," NJSBA (May 2023)
  • "Navigating Management Service, Vendor Contractor, and Financial Source Agreements," NJSBA 5th Annual Cannabis Symposium (March 2023)
  • "Mock Negotiation: Buying/Selling a License," INCBA Cannabis Law Session at MJBizCon (November 2022)
  • "Latest Developments in Cannabis Law," NJSBA Cannabis Law Special Committee (October 2022)
  • "Looking Beyond Cannabis: Alternative Products and Emerging Therapies," New Jersey Society of Certified Public Accountants Cannabis Conference (August 2022)
  • "Cannabis Licensing in New Jersey: What You Need to Know as the Businesses Light Up," NJSBA Annual Meeting and Convention (May 2022)
  • "Effective Verbal Communication in Person and Virtually," AHLA Women's Forum Virtual Conference (March 2022)
  • "Advising Physicians About Super Groups – A Mardi Gras Parade of Issues," AHLA Physicians and Hospitals Law Institute (February 2022)
  • "COVID-19 Vaccine Mandates," NJICLE Health & Hospital Law Section (November 2021)
  • "Representing Physicians and Physician Practices and Navigating Physician-Hospital Alignment and Integration Models, Including Private Equity Relationships," AHLA Fundamentals of Health Law (November 2021)
  • "Latest Developments in Cannabis Law: The New Personal Use Cannabis Regulations," NJICLE (October 2021)
  • "2021 Health Law Symposium: Medicinal Cannabis – The Legal and Practical Considerations for Physicians, Hospitals, and Post-Acute Care Facilities," NJICLE (October 2021)
  • "Cannabis Conference: The Legal Lifecycle of a Cannabis Business," New Jersey Society of Certified Public Accountants (July 2021)
  • "The Ins and Outs of Licensing of Recreational Cannabis Businesses in New Jersey," NJICLE (July 2021)
  • "Interstate Commerce of Cannabis – The Impact and Aftermath of Siloed Markets," NJICLE (July 2021)
  • "Overview of the Adult Use Cannabis Laws in New Jersey," NJSBA 2021 Annual Meeting (May 2021)
  • "3rd Annual Cannabis Symposium: An Update on the Regulatory Changes Regarding CBD," NJICLE (April 2021)
  • "Legal 101 for CPAs Serving Cannabis Clients," New Jersey Society of Certified Public Accountants (February 2021)
  • "Hemp and CBD – Legal Implications and Regulations," NJICLE (November 2020)
  • "The Cannabis Law Referendum, You, and Your Clients – What You Need to Know Now," NJICLE (October 2020)
  • "Fundamentals of Representing Physicians," NJICLE (April 2020)

Email Disclaimer

NOTICE: The mailing of this email is not intended to create, and receipt of it does not constitute an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Cancel Accept